Adrian Hargrave, CEO of SEEEN, explains how the Company is now funded through to profitability.  Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,959.00
Bid: 1,961.00
Ask: 1,962.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.051%)
Open: 1,958.00
High: 1,969.00
Low: 1,950.00
Prev. Close: 1,959.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Pandemic fears pummel European stocks into correction territory

Thu, 27th Feb 2020 09:58

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)

* Travel and leisure, basic resources stocks worst hit

* WPP leads losses on STOXX 600 after bleak forecast

* Standard Chartered, AB InBev latest victims of virus
damage

* Hikma Pharma tops STOXX 600 on annual earnings beat
(Adds details, updates to close)

By Ambar Warrick and Thyagaraju Adinarayan

Feb 27 (Reuters) - European stocks marked their weakest
close in more than four months on Thursday, sinking into
correction territory as a jump in coronavirus cases outside
China deepened fears of an economically damaging pandemic.

Investors typically consider a correction in a security or
index to be a drop of 10% or more from its recent peak.

The pan-European STOXX 600 index, which retreated
3.8% for the day, has fallen more than 10% from a record high
hit on Feb. 19.

While strong earnings had caused investors to pause selling
on Wednesday, a spike in infections outside China, particularly
in Italy, saw markets slip back into red.

"From the unshakeable optimism seen at the beginning of the
year, investors have done a complete U-turn switching from
excessive optimism to outright pessimism in less than a week,"
Michael Hewson, chief market analyst at CMC Markets UK, said.

Thursday's sell-off saw more than 97% of the pan-European
STOXX 600 index's constituents trading red, with basic
resources stocks among the worst performers as commodity
prices plunged amid fears of sustained disruptions in the global
supply chain.

"The sell-off in the base metals complex over the last few
days largely reflects the heightened risk-off sentiment or
'fear-factor' across broader riskier assets," Wenyu Yao, senior
commodities strategist at ING wrote in a note.

London-listed miner Evraz Plc was the worst
performing stock in the sector after it posted weak 2019
earnings.

Travel stocks also plummeted, with casino operator
Evolution Gaming Group leading declines. The sector
has shed nearly 15% this week, underperforming its peers by a
wide margin.

Standard Chartered fell 3.5% after the bank said a
key earnings target would take longer to meet as the epidemic
adds to headwinds in China and Hong Kong. The broader bank
sector was also pressured by a drop in bond yields.

The world's largest beer maker, Anheuser-Busch InBev
, plunged nearly 11% after it forecast muted growth in
2020, due in part to the outbreak.

Advertising major WPP tumbled 16%, marking its worst
day since August 1992, after saying it would target flat organic
growth and profit margins in 2020. The stock was the worst
performer on the STOXX 600.

Italian shares, which entered correction territory
on Wednesday, fell 2.7% as the country reported another 100
coronavirus cases nationwide, taking the total to more than 400.

In a sole bright spot, Hikma Pharmaceuticals rose
4.6%, topping the STOXX 600 after it beat expectations with its
annual earnings.
(Reporting by Sruthi Shankar in Bengaluru and Danilo Masoni in
Milan
Editing by Sriraj Kalluvila, Giles Elgood and Frances Kerry)

More News
30 Apr 2021 07:57

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

Read more
30 Apr 2021 07:38

Hikma predicts generics revenue at top of guidance

(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.

Read more
23 Apr 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
21 Apr 2021 12:08

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

Read more
21 Apr 2021 10:06

Hikma resumes asthma drug launch, Vectura pays special dividend

Hikma resumes asthma drug launch, Vectura pays special dividend

Read more
21 Apr 2021 09:01

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

Read more
21 Apr 2021 07:52

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

Read more
21 Apr 2021 07:30

Hikma resumes US launch of 'Advair Diskus' generic

(Sharecast News) - Hikma Pharmaceuticals has resumed the launch of its generic version of GlaxoSmithKline's 'Advair Diskus' in the United States, it announced on Wednesday, following Food and Drug Administration (FDA) approval of an amendment it submitted to its Abbreviated New Drug Application in January.

Read more
19 Apr 2021 16:02

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
16 Apr 2021 14:54

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
31 Mar 2021 17:04

LONDON MARKET CLOSE: Stocks end lower; investors shun Deliveroo

LONDON MARKET CLOSE: Stocks end lower; investors shun Deliveroo

Read more
31 Mar 2021 13:40

Wednesday broker round-up

(Sharecast News) - Hikma: Jefferies upgrades to buy with a target price of 2,870p.

Read more
31 Mar 2021 12:17

LONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut

LONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut

Read more
31 Mar 2021 11:56

Jefferies upgrades Hikma to 'buy'

(Sharecast News) - Analysts at Jefferies upgraded drugmaker Hikma Pharmaceuticals from 'hold' to 'buy' on Wednesday, stating the group's share price was yet to reflect "a series of upcoming product catalysts".

Read more
31 Mar 2021 09:37

BROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma

BROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.